Changeflow GovPing Healthcare USPTO Patent Application for Digital Therapeuti...
Routine Notice Added Final

USPTO Patent Application for Digital Therapeutics Combination Therapy

Favicon for changeflow.com ChangeBridge: Patent Apps - Medical Devices (A61M)
Published November 26th, 2025
Detected March 23rd, 2026
Email

Summary

The USPTO has published patent application US20260080800A1 for a combination therapy involving digital therapeutics and non-digital interventions, such as medicinal agents, aimed at decreasing pro-inflammatory molecules. The application was filed by REMEPY HEALTH LTD.

What changed

This document is a publication of a patent application (US20260080800A1) filed by REMEPY HEALTH LTD. The application describes a combination therapy that integrates digital therapeutics with non-digital interventions, like medicinal agents, to reduce pro-inflammatory molecules. The digital therapeutic delivery methods include sensory inhibition, substitution, or integration.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in the digital therapeutics and combination therapy space, which may impact product development and market strategies for pharmaceutical and medical device companies.

Source document (simplified)

← USPTO Patent Applications

COMBINATION THERAPY WITH DIGITAL THERAPEUTICS FOR IMPROVED IMMUNE FUNCTION

Application US20260080800A1 Kind: A1 Mar 19, 2026

Assignee

REMEPY HEALTH LTD

Inventors

Amir AMEDI, Michal TSUR-SHALEV, Or SHOVAL, Shahar SHELLY, Nira Neomi SAPORTA

Abstract

The presently disclosed subject matter relates to the field of digital therapeutics to decrease pro-inflammatory molecules such as cytokines and chemokines. A primary mode of delivering the digital therapeutics is using sensory means comprising: sensory inhibition, sensory substitution, sensory integration, or a combination thereof. The invention also provides combination therapies that comprise digital interventions together with non-digital interventions such as medicinal agents.

CPC Classifications

G09B 19/00 A61B 5/4088 A61B 5/4848 A61B 5/7475 A61M 21/00 A63F 9/0612 G16B 40/00 G16H 10/20 G16H 10/60 G16H 20/10 G16H 20/17 G16H 20/30 G16H 20/70 G16H 50/30 A61M 2021/0022 A61M 2021/0027 A61M 2021/005 A63F 2300/10 A63F 2300/30 A63F 2300/8094

Filing Date

2025-11-26

Application No.

19401541

View original document →

Named provisions

COMBINATION THERAPY WITH DIGITAL THERAPEUTICS FOR IMPROVED IMMUNE FUNCTION

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
USPTO
Published
November 26th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260080800A1

Who this affects

Applies to
Drug manufacturers Medical device makers Patients
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Drug Development Digital Therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Pharmaceuticals Medical Devices

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Medical Devices (A61M) publishes new changes.

Free. Unsubscribe anytime.